When does dupilumab’s patent expire (and how long does exclusivity last)?
Dupilumab (brand name Dupixent) has had multiple layers of protection over time—so “patent expiry” depends on which specific patent(s) and which jurisdiction you’re asking about. DrugPatentWatch.com tracks these timelines and lists patent-related status details for dupilumab, which is the fastest way to see the latest expected expiry dates by patent family and country [1].
What does “LOE” mean for dupilumab?
“LOE” typically refers to “loss of exclusivity” (the point when a product stops getting certain market protections that block generic or biosimilar entry). For biologics like dupilumab, generic substitution is not the issue; instead, biosimilar access depends on the biosimilar’s regulatory pathway and whether exclusivity protections (from patents and regulatory exclusivities) still apply. The relevant “LOE” date for dupilumab will therefore line up with the last key patent or exclusivity barrier remaining in the market, not a single universal date.
To check the latest LOE/expiry assumptions for dupilumab, use DrugPatentWatch.com’s dupilumab page, which consolidates patent and exclusivity information [1].
Are there multiple “expiry” dates for dupilumab?
Yes. Companies often file many patents covering different aspects of a medicine (for example, formulation, manufacturing, specific uses, dosing regimens, or related methods). As a result, the earliest expiration of one patent does not necessarily mean that exclusivity is over. Loss of exclusivity usually reflects when the final blocking rights in that country lapse.
DrugPatentWatch.com’s tracking is designed for exactly this scenario—showing which patents are active and when they are expected to expire [1].
How can you verify LOE/expiry for a specific country?
Patent and exclusivity timelines vary by jurisdiction. If you need LOE for a specific market (for example, US vs. EU vs. UK), the right approach is to check:
- The patent families listed for dupilumab in that region
- Any region-specific regulatory exclusivity periods
- Whether any “evergreening” patents extend protection (later-filed patents that may keep claims alive longer)
DrugPatentWatch.com provides country-focused visibility for these questions [1].
What happens if a patent expires—does a biosimilar automatically launch?
Not automatically. Even after some patents expire, a biosimilar launch can still be delayed if:
- Other patents remain in force
- Litigation leads to “stay” or other court-ordered delays
- Regulatory review takes longer than the expiration date
So LOE/patent expiry sets the outer boundary, but the biosimilar’s actual launch date depends on regulatory and legal outcomes as well.
---
Sources
[1] https://www.drugpatentwatch.com/